progressive MS

#ACTRIMS2018 – MediciNova Presents Positive Results from SPRINT-MS Trial Evaluating Ibudilast in Progressive MS

Top-line results from a clinical trial evaluating the investigational oral therapy ibudilast for progressive multiple sclerosis (MS) show that the therapy led to a significant reduction of brain atrophy in patients when compared to controls. Robert Naismith, MD, one of the study’s principal researchers from Washington University in St. Louis,…

Clomipramine, an Antidepressant, Shows Potential in Treating Progressive MS in Early Study

Clomipramine, an approved antidepressant, shows potential in treating people with progressive multiple sclerosis (MS)  — a disease form with few treatments — by protecting nerves from various processes thought to underly progressive MS, early research shows. The lab and animal study, which focused on already-approved treatments, was titled “Systematic…

MMJ Hires Lead Investigator for Phase 2 Trials of Medicinal Cannabis to Treat Progressive MS

MMJ BioScience, an affiliate of medical cannabis research company MMJ International Holdings, has hired a principal investigator to lead clinical trials exploring potential therapeutic applications of cannabinoids in progressive multiple sclerosis (MS). Dr. Bianca Weinstock-Guttman, a neurology professor at the State University of New York at Buffalo, is executive director…

Study Links MIF, D-DT Molecules to Progressive Multiple Sclerosis Development

Two molecules known to regulate cellular signaling contribute to the underlying mechanism of progressive multiple sclerosis, found a recent study conducted by investigators at Oregon Health & Science University and Yale University School of Medicine. These two proteins are related to each other, as they participate in the same cellular signaling process that regulate the immune system's response. Previous studies have blamed them for the worsening of several autoimmune and inflammatory disorders including rheumatoid arthritis, systemic sclerosis and systemic lupus erythematosus. The research team found that patients with progressive MS had higher levels of MIF and D-DT proteins than those with the relapsing-remitting form of the disease. In addition, these proteins inflamed the central nervous system, making patients sicker. An analysis of the genes that encode the proteins revealed that higher levels of MIF were linked to the presence of two genetic variants that are more frequent in patients — particularly males — with progressive disease. Researchers confirmed their findings with animal models of MS-like disease that were genetically engineered to lack MIF and D-DT proteins. Taken together, this finding suggests that a simple genetic test could identify patients carrying the MIF genetic susceptibility — and therefore more likely to develop a severe form of MS. This study was partially funded by the National Institutes of Health, the National Multiple Sclerosis Society, the Rocky Mountain MS Center Tissue Bank and the U.S Department of Veterans Affairs.

MedDay’s New Phase 3 Trial and Belief in Biotin’s Potential to Treat Progressive MS: An Interview with Dr. Frédéric Sedel

A global Phase 3 clinical trial assessing MD1003 — also known as high-dose biotin — for progressive multiple sclerosis (MS) might lead to the approval of one of the first treatments helping select progressive patients to improve. The trial aims to prove that high-dose biotin can reverse disability in non-active progressive MS.

High dose biotin protocol – my nine month update!

Nine months ago I started the high dose biotin protocol. I did so in an effort to slow the progression of my primary progressive multiple sclerosis. This is the link for my first article in August detailing the high dose biotin protocol and my results at that time.

Progressive MS Alliance Awards $18M to 3 Research Projects into Disease Treatments, Expanded Testing

The International Progressive Multiple Sclerosis (MS) Alliance, a worldwide group of MS organizations that support research efforts, has awarded three, four-year grants — called Collaborative Network Awards, and worth $6 million each — to speed work into potential treatments for progressive MS. Found in about 15 percent of all initially diagnosed…

#CMSC16 – Novel Model of Home Care for Patients with Progressive MS Proven Beneficial, Increased Patients’ Satisfaction

A new model of care implemented to address the needs of patients with progressive multiple sclerosis (MS) and their caregivers has proven beneficial by reducing hospital stays, avoiding major care expenses, and improving patients’ satisfaction. The model has been tested in MS patients with high disability scores, and preliminary results of…

MedDay Presents Phase 3 Extension Data on Potential Drug to Treat Progressive MS

Data from an extension phase of a Phase 3 clinical trial, given in an oral presentation by MedDay, reported that the biotin  MD1003 showed effectiveness over time as a possible treatment of non-active, progressive multiple sclerosis (MS). The data were presented at the recent 2nd Congress of the European Academy of Neurology (EAN) in Denmark by Professor Ayman Tourbah,…

Opexa’s CEO Gives Update on T-Cell Therapy at Vatican Conference

Opexa Therapeutics, Inc., announced that its president and chief executive officer, Neil K. Warma, recently gave a presentation on immunotherapy and its potential for treating autoimmune disorders, including multiple sclerosis, at the recent Cellular Horizons: The Third International Conference on the Progress of Regenerative Medicine and its Cultural Impact held at the Vatican. Neil…

Potential Progressive MS Treatment, Ibudilast, Approved for Fast Track Development by FDA

MediciNova, Inc., announced that MN-166 (ibudilast) has been approved for “fast track” development by the U.S. Food and Drug Administration (FDA) as a potential treatment for progressive multiple sclerosis (MS). Progressive MS includes both the primary progressive (PPMS) and secondary progressive (SPMS) forms of the disease. MediciNova’s MN-166 was licensed from Kyorin Pharmaceuticals for its potential…

Kinase Inhibitor, Masitinib, Spotted for Potential to Treat Neurological Disorders Like PPMS

AB Science recently reported the publication of four peer-reviewed and independent research papers that add to the growing recognition of masitinib, the company’s lead compound, as a promising treatment for neurological and neurodegenerative diseases, including progressive multiple sclerosis (MS), Alzheimer’s disease (AD), and amyotrophic lateral sclerosis (ALS). Tyrosine kinase inhibitors (TKIs)…